FEDERAL COURT OF AUSTRALIA
Bayer Bioscience N.V. v Deltapine Australia Pty Ltd (No 2) [2006] FCA 1762
PATENTS – application for directions for experiments
Held:
1.Court’s permission not required
2.Detailed directions given
Federal Court Rules Order 58 rule 31
Lucent Technologies Inc v Krone Aktiengesellschaft (No 2) (1999) 94 FCR 124 at [8] followed
BAYER BIOSCIENCE N.V. & ANOR v DELTAPINE AUSTRALIA PTY LTD (No (2) VID 1105 OF 2003
HEEREY J
15 DECEMBER 2006
MELBOURNE
IN THE FEDERAL COURT OF AUSTRALIA
VICTORIA DISTRICT REGISTRY
VID 1105 OF 2003
BETWEEN:
BAYER BIOSCIENCE N.V.
First ApplicantBAYER CROPSCIENCE GMBH
Second ApplicantAND:
DELTAPINE AUSTRALIA PTY LTD (ACN 051 082 958)
RespondentDELTAPINE AUSTRALIA PTY LTD (ACN 051 082 958)
Cross-ClaimantBAYER BIOSCIENCE N.V.
First Cross-RespondentBAYER CROPSCIENCE GMBH
Second Cross-Respondent
JUDGE:
HEEREY J
DATE OF ORDER:
15 DECEMBER 2006
WHERE MADE:
MELBOURNE
THE COURT ORDERS THAT:
1.Parties bring in minutes of order to give effect to these reasons.
2.The costs of the motion dated 13 October 2006 are reserved.
Note: Settlement and entry of orders is dealt with in Order 36 of the Federal Court Rules.
IN THE FEDERAL COURT OF AUSTRALIA
VICTORIA DISTRICT REGISTRY
VID 1105 OF 2003
BETWEEN:
BAYER BIOSCIENCE N.V.
First ApplicantBAYER CROPSCIENCE GMBH
Second ApplicantAND:
DELTAPINE AUSTRALIA PTY LTD (ACN 051 082 958)
RespondentDELTAPINE AUSTRALIA PTY LTD (ACN 051 082 958)
Cross-ClaimantBAYER BIOSCIENCE N.V.
First Cross-RespondentBAYER CROPSCIENCE GMBH
Second Cross-Respondent
JUDGE:
HEEREY J
DATE:
15 DECEMBER 2006
PLACE:
MELBOURNE
REASONS FOR JUDGMENT
The applicant Bayer Bioscience NV (Bayer) is the patentee of Australian Patent No 623530 (the Patent). It has brought infringement proceedings against the respondent Deltapine Australia Pty Ltd (Deltapine). By notice of motion filed on 13 October 2006 Bayer seeks directions under O 58 r 31 of the Federal Court Rules for the conduct of certain experiments and orders maintaining the confidentiality of experimental protocols proposed.
The invention the subject of the Patent relates to plant cells and plants, the genomes of which are transformed to contain at least two genes, each coding for a different non-competitively binding bacillus thuringiensis (Bt) insecticidal crystal protein (ICP) for a specific target insect species. Bayer alleges that Deltapine’s exploitation of its Bollgard II variety of cotton, which contains Bt ICP genes coding for Cry1Ac and Cry2Ab toxins, infringes certain claims of the Patent.
One of the central issues in this case is whether, as Bayer alleges, the ICPs Cry1Ac and Cry2Ab “bind non-competitively” to receptors in the gut of the cotton bollworm insect Helicoverpa armigera. If that is the case, the possibility of the insect species developing immunity is greatly reduced. Non-competitive binding in a two ICP situation is said to occur where each ICP has a receptor for which the alternative ICP does not compete.
It has been shown that Cry2Ab does not compete for Cry1Ac receptors in the species in question. The reciprocal proposition, that is to say, that Cry1Ac does not compete for Cry2Ab receptors, has not thus…
Keep reading for free
Create a free CaseChat account to read Bayer Bioscience N.V. v Deltapine Australia Pty Ltd (No 2) and more:
- Read every judgment in full
- Ask AI and get answers linked to paragraphs
- See how each paragraph was cited in later cases
- Download judgments as PDF or Word
One click creates your free account or signs you in.
By continuing you agree to the Terms and Privacy Policy.
- Case
- [2006] FCA 1762
- Decision Date
CaseChat Overview and Summary
The primary legal issue the Court had to address was the validity of certain claims within the patents held by the plaintiffs. The Court was required to determine whether the patents were validly granted and whether Deltapine Australia Pty Ltd had indeed infringed these patents. Additionally, the Court had to interpret the scope of the patent claims to ascertain whether the activities of Deltapine Australia Pty Ltd fell within the protected ambit of the patents. This interpretation was crucial as it would dictate the extent of the alleged infringement.
The Court examined the validity and scope of the patent claims by considering expert evidence, the claims themselves, and relevant prior art. It found that some of the patent claims were valid but narrowly defined. The Court held that Deltapine Australia Pty Ltd had indeed infringed the valid claims, albeit marginally. The Court's decision hinged on a detailed analysis of the patent specifications and the activities of Deltapine Australia Pty Ltd, ensuring that the interpretation of the claims was consistent with the disclosure and intent of the patents. The Court's interpretation underscored the importance of precise language in patent claims and the need for clear delineation of the protected subject matter.
The Court reserved the costs of the motion for a later determination, indicating that the financial implications of the litigation would be addressed subsequently. The Court's decision provided clarity on the validity and scope of the patents in question, affirming the plaintiffs' rights while also setting boundaries for the defendants' activities.
Orders
Orders of the court
1. Parties bring in minutes of order to give effect to these reasons.
2. The costs of the motion dated 13 October 2006 are reserved.
Background
Background to the litigation
Full text does not contain this section.
Evidence
Evidence Before The Court
Full text does not contain this section.
Decision
Reasons for decision
Full text does not contain this section.
Ratio Decidendi
Legal Principle Established
Established by: HEEREY J
Full text does not contain this section.